Twist Bioscience TWST
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Twist Bioscience (TWST) Business Model and Operations Summary
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Key Insights
Twist Bioscience (TWST) Core Market Data and Business Metrics
Latest Closing Price
$38.94Market Cap
$2.34 BillionPrice-Earnings Ratio
-11.52Total Outstanding Shares
59.65 Million SharesTotal Employees
923Dividend
No dividendIPO Date
October 31, 2018SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
681 Gateway Blvd., South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-8.77 Million |
| Exchange Gains/Losses | $-43,000 |
| Net Cash Flow | $-45.06 Million |
| Net Cash Flow From Financing Activities | $26.31 Million |
| Net Cash Flow, Continuing | $-45.01 Million |
| Net Cash Flow From Investing Activities | $-8.77 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-3.38 |
| Net Income/Loss | $-197.31 Million |
| Basic Average Shares | $175.30 Million |
| Income/Loss From Continuing Operations Before Tax | $-196.78 Million |
| Benefits Costs and Expenses | $526.96 Million |
| Operating Expenses | $355.72 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-197.40 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-84,000 |
| Comprehensive Income/Loss Attributable To Parent | $-197.40 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Accounts Payable | $7.50 Million |
| Other Non-current Assets | $162.60 Million |
| Liabilities And Equity | $608.58 Million |
| Current Assets | $345.31 Million |
| Assets | $608.58 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||